According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

A court-appointed special master recommended a bid backed by Gold Reserve and Koch over a rival hedge-fund offer. Krispy Kreme's top finance executive, Jeremiah Ashukian, is leaving the doughnut maker ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

The actor is raising awareness of clinical trials for cancer in partnership with “GMA” sponsor Eli Lilly & Co.

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...